InsightfulValue
← Home

GlaxoSmithKline
GlaxoSmithKline

Pharma / Pharma and biotechnology


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

βœ… Download "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” totally free!

Price
Live  
Overview
GlaxoSmithKline (GSK) is a multinational pharmaceutical and healthcare company headquartered in Brentford, London. The company was formed in 2000 through the merger of British company Glaxo Wellcome and American company SmithKline Beecham. It is one of the largest pharmaceutical companies in the world and is focused on the research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products.
History:
The history of GlaxoSmithKline can be traced back to the establishment of two independent companies: Joseph Nathan and Co. in New Zealand in 1873 and Burroughs Wellcome & Company in the UK in 1880. In 1995, Glaxo Wellcome PLC was formed through the merger of Glaxo and Burroughs Wellcome. SmithKline Beecham PLC was formed in 1989 through the merger of SmithKline Beckman Corporation and Beecham Group PLC. In 2000, the two companies merged to form GlaxoSmithKline.
Products:
GSK's product portfolio includes prescription medicines, vaccines, and consumer healthcare products. Its prescription medicines cover a broad range of therapeutic areas, including respiratory, HIV, oncology, and neurosciences. The company also offers vaccines for diseases such as influenza, meningitis, and shingles. Its consumer healthcare products include over-the-counter medicines, oral care, nutrition, and skin health products.
Research and Development:
GSK has a strong focus on research and development (R&D) and invests heavily in this area. The company has R&D facilities in the UK, US, Belgium, and China, among others. Its R&D efforts are focused on discovering and developing new medicines and vaccines for a wide range of diseases and conditions. GSK collaborates with academic institutions, governments, and other industry partners to advance its research efforts.
Corporate Responsibility:
GSK is committed to operating ethically and responsibly, with a focus on sustainability and corporate social responsibility. The company has various initiatives in place to reduce its environmental impact and improve access to healthcare for underserved populations. It also has policies in place to ensure ethical business practices and compliance with laws and regulations.
Financials:
In 2020, GSK reported revenues of Β£34 billion and a net income of Β£5.5 billion. The company employs over 100,000 people globally and has a presence in over 150 countries. Its primary stock exchange listings are on the London Stock Exchange and the New York Stock Exchange.
Partnerships:
GSK has formed partnerships with various organizations to further its research and development efforts, expand its product portfolio, and improve access to healthcare. Some notable collaborations include:
- Joint ventures with Pfizer in the areas of consumer healthcare and HIV treatment
- Collaboration with Sanofi to develop a COVID-19 vaccine
- Partnership with Innoviva to develop respiratory treatments
- Collaboration with Vir Biotechnology to develop pandemic treatments
- Partnership with the Bill & Melinda Gates Foundation to develop vaccines for malaria and tuberculosis
Summary:
GlaxoSmithKline is a multinational pharmaceutical and healthcare company focused on research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products. It has a strong history and presence in the market, with a commitment to corporate responsibility and ethical business practices. The company has a diverse range of products and partnerships that contribute to its strong financial performance.
What is special about the company?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

VGhlcmUgYX JlIHNldmVy YWwga2V5IG ZhY3RvcnMg dGhhdCBtYW tlIEdsYXhv U21pdGhLbG luZSAoR1NL KSBhIHVuaX F1ZSBhbmQg c3BlY2lhbC Bjb21wYW55 Ojxicj4xLi BTaXplIGFu ZCBTY29wZT ogR1NLIGlz IG9uZSBvZi B0aGUgbGFy Z2VzdCBwaG FybWFjZXV0 aWNhbCBjb2 1wYW5pZXMg aW4gdGhlIH dvcmxkLCB3 aXRoIG9wZX JhdGlvbnMg aW4gb3Zlci AxNTAgY291 bnRyaWVzIG FuZCBhIHZh c3QgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzIHNwYW5u aW5nIHByZX NjcmlwdGlv biBtZWRpY2 luZXMsIGNv bnN1bWVyIG hlYWx0aGNh cmUsIGFuZC B2YWNjaW5l cy48YnI+Mi 4gSGlzdG9y eSBhbmQgTG VnYWN5OiBH U0sgaGFzIG EgcmljaCBo aXN0b3J5IG RhdGluZyBi YWNrIHRvIH RoZSAxOXRo IGNlbnR1cn ksIHdpdGgg dGhlIG1lcm dlciBvZiBH bGF4b1dlbG xjb21lIGFu ZCBTbWl0aE tsaW5lIEJl ZWNoYW0gaW 4gMjAwMCBz b2xpZGlmeW luZyBpdHMg cG9zaXRpb2 4gYXMgYSBt YWpvciBwbG F5ZXIgaW4g dGhlIGhlYW x0aGNhcmUg aW5kdXN0cn kuPGJyPjMu IFJlc2Vhcm NoIGFuZCBE ZXZlbG9wbW VudDogSW5u b3ZhdGlvbi BhbmQgcmVz ZWFyY2ggYX JlIGF0IHRo ZSBoZWFydC BvZiBHU0sn cyBidXNpbm Vzcywgd2l0 aCBzaWduaW ZpY2FudCBp bnZlc3RtZW 50cyBtYWRl IGluIGRpc2 NvdmVyaW5n IGFuZCBkZX ZlbG9waW5n IG5ldyBtZW RpY2luZXMg dG8gbWVldC B1bm1ldCBt ZWRpY2FsIG 5lZWRzLjxi cj40LiBDb2 1taXRtZW50 IHRvIEdsb2 JhbCBIZWFs dGg6IEdTSy dzIG1pc3Np b24gaXMgdG 8gaW1wcm92 ZSB0aGUgcX VhbGl0eSBv ZiBodW1hbi BsaWZlIGJ5 IGVuYWJsaW 5nIHBlb3Bs ZSB0byBkby Btb3JlLCBm ZWVsIGJldH RlciwgYW5k IGxpdmUgbG 9uZ2VyLiBU aGUgY29tcG FueSBpcyBk ZWRpY2F0ZW QgdG8gYWRk cmVzc2luZy BnbG9iYWwg aGVhbHRoIG NoYWxsZW5n ZXMsIHN1Y2 ggYXMgaW5m ZWN0aW91cy BkaXNlYXNl cyBhbmQgYW NjZXNzIHRv IGhlYWx0aG NhcmUgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMuPG JyPjUuIERp dmVyc2UgUG 9ydGZvbGlv OiBHU0sgaG FzIGEgZGl2 ZXJzZSBwb3 J0Zm9saW8g b2YgcHJvZH VjdHMsIGlu Y2x1ZGluZy BtYXJrZXQt bGVhZGluZy BicmFuZHMg c3VjaCBhcy BBZHZhaXIs IFNlbnNvZH luZSwgYW5k IEZsb25hc2 UuIEl0IGFs c28gaGFzIG Egc3Ryb25n IHBpcGVsaW 5lIG9mIHBv dGVudGlhbC BuZXcgbWVk aWNpbmVzIG FuZCB2YWNj aW5lcyBpbi B2YXJpb3Vz IHN0YWdlcy BvZiBkZXZl bG9wbWVudC 48YnI+Ni4g Q29ycG9yYX RlIFJlc3Bv bnNpYmlsaX R5OiBHU0sg aXMgY29tbW l0dGVkIHRv IGNvbmR1Y3 RpbmcgYnVz aW5lc3Mgcm VzcG9uc2li bHkgYW5kIG V0aGljYWxs eSwgd2l0aC BhIGZvY3Vz IG9uIHN1c3 RhaW5hYmls aXR5LCBlbn Zpcm9ubWVu dGFsIHN0ZX dhcmRzaGlw LCBhbmQgaW 1wcm92aW5n IGFjY2Vzcy B0byBoZWFs dGhjYXJlIG ZvciB1bmRl cnNlcnZlZC Bwb3B1bGF0 aW9ucy48Yn I+Ny4gQ3Vs dHVyZSBhbm QgVmFsdWVz OiBHU0sgcH JpZGVzIGl0 c2VsZiBvbi BpdHMgZGl2 ZXJzZSBhbm QgaW5jbHVz aXZlIHdvcm twbGFjZSBj dWx0dXJlLC BndWlkZWQg YnkgYSBzZX Qgb2YgY29y ZSB2YWx1ZX MgdGhhdCBw cmlvcml0aX plIGludGVn cml0eSwgcm VzcGVjdCBm b3IgcGVvcG xlLCBhbmQg dHJhbnNwYX JlbmN5Ljxi cj5PdmVyYW xsLCBHU0sn cyBzaXplLC BoaXN0b3J5 LCBmb2N1cy BvbiBpbm5v dmF0aW9uIG FuZCBnbG9i YWwgaGVhbH RoLCBkaXZl cnNlIHBvcn Rmb2xpbywg Y29tbWl0bW VudCB0byBj b3Jwb3JhdG UgcmVzcG9u c2liaWxpdH ksIGFuZCBz dHJvbmcgY3 VsdHVyZSBt YWtlIGl0IG EgdW5pcXVl IGFuZCBlc3 RlZW1lZCBj b21wYW55IG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 4=
What the company's business model?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ“˜ Claim your free eBook: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

R2xheG9TbW l0aEtsaW5l IChHU0spIG lzIGEgZ2xv YmFsIHBoYX JtYWNldXRp Y2FsIGFuZC BoZWFsdGhj YXJlIGNvbX BhbnkgZm9j dXNlZCBvbi BpbXByb3Zp bmcgdGhlIG hlYWx0aCBh bmQgd2VsbC 1iZWluZyBv ZiBwZW9wbG UgYXJvdW5k IHRoZSB3b3 JsZC4gVGhl IGNvbXBhbn kncyBidXNp bmVzcyBtb2 RlbCBpcyBi YXNlZCBvbi Bmb3VyIGtl eSBjb21wb2 5lbnRzOiA8 YnI+MS4gUm VzZWFyY2gg YW5kIERldm Vsb3BtZW50 IChSJkQpOi BHU0sgaW52 ZXN0cyBoZW F2aWx5IGlu IFImRCB0by BkZXZlbG9w IG5ldyBtZW RpY2luZXMs IHZhY2Npbm VzLCBhbmQg Y29uc3VtZX IgaGVhbHRo Y2FyZSBwcm 9kdWN0cy4g VGhlIGNvbX BhbnkgaGFz IHJlc2Vhcm NoIGNlbnRl cnMgYW5kIH BhcnRuZXJz aGlwcyB3b3 JsZHdpZGUg dG8gZHJpdm UgaW5ub3Zh dGlvbiBhbm QgaW1wcm92 ZSBwYXRpZW 50IGhlYWx0 aCBvdXRjb2 1lcy48YnI+ Mi4gQ29tbW VyY2lhbGl6 YXRpb24gYW 5kIE1hcmtl dGluZzogR1 NLIHNlbGxz IGl0cyBwcm 9kdWN0cyB0 byBwYXRpZW 50cywgaGVh bHRoY2FyZS Bwcm9mZXNz aW9uYWxzLC BhbmQgb3Ro ZXIgY3VzdG 9tZXJzIHRo cm91Z2ggYS B2YXJpZXR5 IG9mIGNoYW 5uZWxzLiBU aGlzIGluY2 x1ZGVzIHRy YWRpdGlvbm FsIHNhbGVz IGFuZCBtYX JrZXRpbmcg ZWZmb3J0cy wgYXMgd2Vs bCBhcyBkaW dpdGFsIGFu ZCBlLWNvbW 1lcmNlIGlu aXRpYXRpdm VzLjxicj4z LiBTdHJhdG VnaWMgUGFy dG5lcnNoaX BzOiBHU0sg Y29sbGFib3 JhdGVzIHdp dGggYSByYW 5nZSBvZiBw YXJ0bmVycy wgaW5jbHVk aW5nIGFjYW RlbWljIGlu c3RpdHV0aW 9ucywgYmlv dGVjaCBjb2 1wYW5pZXMs IGFuZCBvdG hlciBwaGFy bWFjZXV0aW NhbCBjb21w YW5pZXMsIH RvIGFkdmFu Y2UgaXRzIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCBlZmZvcn RzLjxicj40 LiBEaXZlcn NpZmllZCBQ b3J0Zm9saW 86IEdTSyBv cGVyYXRlcy BpbiB0aHJl ZSBtYWluIG FyZWFzIC0g cGhhcm1hY2 V1dGljYWxz LCB2YWNjaW 5lcywgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUuIF RoaXMgZGl2 ZXJzaWZpZW QgcG9ydGZv bGlvIGhlbH BzIG1pdGln YXRlIHJpc2 tzIGFuZCBh bGxvd3MgdG hlIGNvbXBh bnkgdG8gYm VuZWZpdCBm cm9tIHRoZS BkaWZmZXJl bnQgZ3Jvd3 RoIHRyZW5k cyBhbmQgcm VndWxhdG9y eSBsYW5kc2 NhcGVzIGFj cm9zcyB0aG VzZSBzZWN0 b3JzLjxicj 5JbiBhZGRp dGlvbiwgR1 NLIGhhcyBh IHN0cm9uZy Bmb2N1cyBv biBzdXN0YW luYWJpbGl0 eSBhbmQgc2 9jaWFsIHJl c3BvbnNpYm lsaXR5LCBp bnRlZ3JhdG luZyB0aGVz ZSBwcmluY2 lwbGVzIGlu dG8gaXRzIG J1c2luZXNz IG9wZXJhdG lvbnMgYW5k IGRlY2lzaW 9uLW1ha2lu Zy4gVGhlIG NvbXBhbnkg aXMgYWxzby Bjb21taXR0 ZWQgdG8gcH JpY2luZyBp dHMgcHJvZH VjdHMgcmVz cG9uc2libH kgYW5kIGVu c3VyaW5nIG FjY2VzcyB0 byBtZWRpY2 luZXMgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMu
Interesting facts about the company
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ“₯ Get our free eBook now: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3Mvbn VkRDBMNmt1 eFY4RFdsVX RKQjgud2Vi cCIgYWx0PS JHbGF4b1Nt aXRoS2xpbm UiIHRpdGxl PSJHbGF4b1 NtaXRoS2xp bmUiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2xh eG9TbWl0aE tsaW5lPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TmiBZb3Vy IGZyZWUgY2 9weSBvZiA8 aT4iVGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrcyI8L2 k+IGlzIHdh aXRpbmcKIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9wPgoKIC AgICAgICAg ICAgICAgIC AgICAgICAg PCEtLQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdtYXJn aW4tdG9wOi AxMnB4OyBm b250LXNpem U6IDEzcHg7 IGNvbG9yOi AjNDQ0Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG 5vdyBhbmQg Z2V0IG91ci BmcmVlIGVC b29rIAogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGI+VG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcz wvYj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC 0tPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8IS 0tCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxkaX Ygc3R5bGU9 J21hcmdpbi 10b3A6IDE2 cHg7IGZvbn Qtc2l6ZTog MTRweDsgY2 9sb3I6ICM0 NDQ7IGZvbn QtZmFtaWx5 OiAtYXBwbG Utc3lzdGVt LCBCbGlua0 1hY1N5c3Rl bUZvbnQsIF NlZ29lIFVJ LCBSb2JvdG 8sIEhlbHZl dGljYSBOZX VlLCBzYW5z LXNlcmlmOy BsaW5lLWhl aWdodDogMS 42Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBIYXZl IHlvdSBoZW FyZCBhYm91 dCBvdXIgc2 hvcnQgPHN0 cm9uZyBzdH lsZT0nZm9u dC13ZWlnaH Q6IDYwMDsn PkRhaWx5IF ZpZGVvIE5l d3NsZXR0ZX I8L3N0cm9u Zz4/CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8YSBocm VmPSdodHRw czovL3d3dy 5pbnNpZ2h0 ZnVsdmFsdW UuY29tL25l d3NsZXR0ZX IucGhwJyB0 YXJnZXQ9J1 9ibGFuaycg c3R5bGU9J2 NvbG9yOiAj MDA3QkZGOy B0ZXh0LWRl Y29yYXRpb2 46IG5vbmU7 IGZvbnQtd2 VpZ2h0OiA1 MDA7IG1hcm dpbi1sZWZ0 OiA2cHg7Jz 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBGaW5k IG91dCBtb3 JlCiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2E+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgCiAgIC AgICAgCiAg ICAgICAgPH NwYW4gY2xh c3M9J2JsdX JyZWQtdGV4 dCc+CiAgIC AgICAgICAg IE1TNGdSMn hoZUcgOVRi V2wwYUV0cy BhVzVsSUds eklHIEVnUW 5KcGRHbHog YUNCdGRXeD BhVyA1aGRH bHZibUZzIE lIQm9ZWEp0 WVcgTmxkWF JwWTJGcyBJ R052YlhCaG JuIGtzSUhk cGRHZ2cgYU dWaFpIRjFZ WCBKMFpYSn pJR2x1IElF eHZibVJ2Ym kgd2dSVzVu YkdGdSBaQz Q4WW5JK01p IDRnVkdobE lHTnYgYlhC aGJua2dhRy BGeklHRWdi Rzl1IFp5Qm 9hWE4wYjMg SjVMQ0JrWV hScCBibWNn WW1GamF5IE IwYnlCaElI Qm8gWVhKdF lXTjVJRyA5 d1pXNWxaQ0 JpIGVTQkti M05sY0cgZ2 dUbUYwYUdG dSBJR2x1SU U1bGR5IEJh WldGc1lXNW sgSUdsdUlE RTRNeiBBdV BHSnlQak11 IElGUm9aU0 JqYjIgMXdZ VzU1SUhkaC BjeUJtYjNK dFlXIHhzZV NCbWIzVnUg WkdWa0lHbH VJRCBFNU1E WWdZbmtnIF NtOXpaWEJv SUUgVmtkMk Z5WkNCTyBZ WFJvWVc0Z1 lXIDVrSUdo cGN5QmkgY2 05MGFHVnlM VyBsdUxXeG hkeXdnIFZH aHZiV0Z6SU UgaHZiR3h2 ZDJGNSBMQ0 JoY3lCaElI IE50WVd4c0 lIQm8gWVhK dFlXTjVJRy BsdUlFeHZi bVJ2IGJpND hZbkkrTkMg NGdWR2hsSU c1aCBiV1Vn UjJ4aGVHID hnWTI5dFpY TWcgWm5Kdm JTQjBhRyBV Z1ptbHljM1 FnIGNISnZa SFZqZEMgQj BhR0YwSUhS byBaU0JqYj Ixd1lXIDU1 SUhCeWIyUj EgWTJWa0xD QjNhRyBsam FDQjNZWE1n IFlTQmtjbW xsWkMgQnRh V3hySUhCeS BiMlIxWTNR Z1kyIEZzYk dWa0lFZHMg WVhodkxqeG ljaiA0MUxp QkhiR0Y0IG J5QnRaWEpu WlcgUWdkMm wwYUNCWCBa V3hzWTI5dF pTIEJwYmlB eE9UazEgSU hSdklHWnZj bSAwZ1IyeG hlRzhnIFYy VnNiR052Yl cgVXNJSGRv YVdObyBJSF JvWlc0Z2JX IFZ5WjJWa0 lIZHAgZEdn Z1UyMXBkRy BoTGJHbHVa U0JDIFpXVm phR0Z0SUcg bHVJREl3TU RBZyBkRzhn Wm05eWJTIE JIYkdGNGIx TnQgYVhSb1 MyeHBibSBV dVBHSnlQal l1IElFZHNZ WGh2VTIgMX BkR2hMYkds dSBaU0JwY3 lCamRYIEp5 Wlc1MGJIa2 cgYjI1bElH OW1JSCBSb1 pTQnNZWEpu IFpYTjBJSE JvWVggSnRZ V05sZFhScC BZMkZzSUdO dmJYIEJoYm 1sbGN5QnAg YmlCMGFHVW dkMiA5eWJH UXNJSGRwIG RHZ2djbVYy WlcgNTFaU0 J2WmlCdiBk bVZ5SUNRME 1TIEJpYVd4 c2FXOXUgSU dsdUlESXdN aiBBdVBHSn lQamN1IElG Um9aU0JqYj IgMXdZVzU1 SUdseiBJR0 VnYldGcWIz IElnY0hKdl pIVmogWlhJ Z2IyWWdkbS BGalkybHVa WE1zIElHTn Zibk4xYlcg VnlJR2hsWV d4MCBhR05o Y21VZ2NIIE p2WkhWamRI TXMgSUdGdV pDQndjbSBW elkzSnBjSF JwIGIyNGdi V1ZrYVcgTn BibVZ6TENC aCBibVFnYV hRZ2FHIEZ6 SUdFZ2NISm wgYzJWdVky VWdhVyA0Z2 IzWmxjaUF4 IE5UQWdZMj kxYm4gUnlh V1Z6TGp4aS BjajQ0TGlC SGJHIEY0Yj FOdGFYUm8g UzJ4cGJtVW dhRyBGeklH RWdiRzl1IF p5Qm9hWE4w YjMgSjVJRz ltSUhOcCBa MjVwWm1sal lXIDUwSUhO amFXVnUgZE dsbWFXTWdZ VyBOb2FXVj JaVzFsIGJu UnpMQ0JwYm 0gTnNkV1Jw Ym1jZyBkR2 hsSUdSbGRt IFZzYjNCdF pXNTAgSUc5 bUlIUnlaVy BGMGJXVnVk SE1nIFptOX lJRWhKVmkg d2dhVzVtYk hWbCBibnBo TENCaGJtIF FnYldGc1lY SnAgWVM0OF luSStPUyA0 Z1ZHaGxJR0 52IGJYQmhi bmtnYUcgRn pJR0ZzYzI4 ZyBZbVZsYm lCcGJuIFp2 YkhabFpDQn AgYmlCelpY WmxjbSBGc0 lHaHBaMmd0 IGNISnZabW xzWlMgQnNa V2RoYkNCai BZWE5sY3l3 Z2FXIDVqYk hWa2FXNW4g SUdFZ0pETW dZbSBsc2JH bHZiaUJ6IF pYUjBiR1Z0 WlcgNTBJR1 p2Y2lCcCBi R3hsWjJGc2 JIIGtnY0hK dmJXOTAgYV c1bklHTmxj biBSaGFXNG daSEoxIFoz TWdZVzVrSU cgRWdjMlYw ZEd4bCBiV1 Z1ZENCM2FY IFJvSUhSb1 pTQlYgVXlC bmIzWmxjbS A1dFpXNTBJ R1p2IGNpQW tOelV3SUcg MXBiR3hwYj I0ZyBabTl5 SUcxaGJuIF ZtWVdOMGRY SnAgYm1jZ1 lXNWtJSCBG MVlXeHBkSG tnIFkyOXVk SEp2YkMgQn djbTlpYkdW dCBjeUJoZE NCaElIIEJz WVc1MElHbH UgSUZCMVpY SjBieSBCU2 FXTnZManhp IGNqNHhNQz RnU1cgNGdN akF5TUN3Zy BSMnhoZUc5 VGJXIGwwYU V0c2FXNWwg SUdKbFkyRn RaUyBCMGFH VWdabWx5IG MzUWdjR2ho Y20gMWhZMl YxZEdsaiBZ V3dnWTI5dG NHIEZ1ZVNC MGJ5QncgYk dWa1oyVWdk RyA4Z2JXRn JaU0JwIGRI TWdZMkZ5WW 0gOXVJR1p2 YjNSdyBjbW x1ZENCdVpY IFF0ZW1WeW J5QmkgZVNB eU1EVXdMai B4aWNqNHhN UzRnIFIyeG hlRzlUYlcg bDBhRXRzYV c1bCBJR2ho Y3lCaElIIE 4wY205dVp5 QmogYjIxdG FYUnRaVyA1 MElIUnZJR0 52IGNuQnZj bUYwWlMgQn piMk5wWVd3 ZyBjbVZ6Y0 c5dWMyIGxp YVd4cGRIa3 MgSUhkcGRH Z2dZUyBCbW IyTjFjeUJ2 IGJpQnBiWE J5YjMgWnBi bWNnWjJ4di BZbUZzSUdo bFlXIHgwYU N3Z2NtVmsg ZFdOcGJtY2 dhWCBSeklH VnVkbWx5IG IyNXRaVzUw WVcgd2dhVz F3WVdOMCBM Q0JoYm1RZ2 MzIFZ3Y0c5 eWRHbHUgWn lCamIyMXRk VyA1cGRHbG xjeUIzIGFH VnlaU0JwZE MgQnZjR1Z5 WVhSbCBjeT Q4WW5JK01U IEl1SUZSb1 pTQmogYjIx d1lXNTVJRy BoaGN5QmhJ R1JwIGRtVn ljMlVnZDIg OXlhMlp2Y2 1ObCBMQ0Iz YVhSb0lHID kyWlhJZ01U QXcgTERBd0 1DQmxiWCBC c2IzbGxaWE 1nIGQyOXli R1IzYVcgUm xJR0Z1WkNC aCBJSE4wY2 05dVp5IEJt YjJOMWN5Qn YgYmlCa2FY WmxjbiBOcG RIa2dZVzVr IElHbHVZMn gxYzIgbHZi aUJwYmlCMC BhR1VnZDI5 eWEzIEJzWV dObExqeGkg Y2o0eE15NG dSMiB4aGVH OVRiV2wwIG FFdHNhVzVs SUcgaGhjeU JoSUhKdiBZ blZ6ZENCd2 FYIEJsYkds dVpTQnYgWm lCdVpYY2da SCBKMVozTW dZVzVrIElI UnlaV0YwYl cgVnVkSE1n YVc0ZyBaR1 YyWld4dmNH IDFsYm5Rc0 lIZHAgZEdn Z2IzWmxjaS BBMU1DQmpZ VzVrIGFXUm hkR1VnZEcg aGxjbUZ3YV dWeiBJR2x1 SUhaaGNtIG x2ZFhNZ2Mz UmggWjJWek lHOW1JRyBO c2FXNXBZMk ZzIElIUnlh V0ZzY3kgND hZbkkrTVRR dSBJRlJvWl NCamIyIDF3 WVc1NUlHaG ggY3lCaElI TjBjbSA5dV p5QndjbVZ6 IFpXNWpaU0 J2YmkgQnpi Mk5wWVd3Zy BiV1ZrYVdF c0lIIGRwZE dnZ2IzWmwg Y2lBNE5Td3 dNRCBBZ1pt OXNiRzkzIF pYSnpJRzl1 SUYgUjNhWF IwWlhJZyBZ VzVrSUdGam RHIGwyWlNC aFkyTnYgZF c1MGN5QnZi aSBCTWFXNX JaV1JKIGJp d2dSbUZqWl cgSnZiMnNz SUdGdSBaQ0 JKYm5OMFlX IGR5WVcwdV BHSnkgUGpF MUxpQkhiRy BGNGIxTnRh WFJvIFMyeH BibVVnYUcg RnpJSEpsWT JWcCBkbVZr SUc1MWJXIF Z5YjNWeklH RjMgWVhKa2 N5QmhibSBR Z2NtVmpiMm R1IGFYUnBi MjRnWm0gOX lJR2wwY3lC MyBiM0pyTE NCcGJtIE5z ZFdScGJtY2 cgWW1WcGJt Y2dibSBGdF pXUWdiMjVs IElHOW1JSF JvWlMgRGln SnhYYjNKcy BaT0tBbVhN Z1RXIDl6ZE NCRmRHaHAg WTJGc0lFTn ZiWCBCaGJt bGxjK0tBIG 5TQmllU0Iw YUcgVWdSWF JvYVhOdyBh R1Z5WlNCSm JuIE4wYVhS MWRHVWcgWm 05eUlERXhJ RyBOdmJuTm xZM1YwIGFY WmxJSGxsWV ggSnpMZz09 CiAgICAgIC AgPC9zcGFu PgogICAgIC AgIAogICAg ICAgIA==
See Company Q&A
GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

πŸ†“ Discover "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free eBook!

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal